Registry of Asthma Patients Initiating DUPIXENT: The RAPID Study
We have recently commenced a new observational study to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life and will include about 1,000 people worldwide.
The study sponsored by Regeneron Pharmaceuticals, Inc. is led by Guys and St Thomas' NHS Foundation Trust with Dr Matthew Martin as our site Principal Investigator.
Registry of Asthma Patients Initiating DUPIXENT® (RAPID)
Why is this study being done?
An observational study is research that aims to collect data (information) on how a certain treatment is used and its effects, without any change to your normal care. The regular visits when the doctor sees you for your asthma are called standard-of-care visits. This study will collect data from tests or measurements carried out during these standard-of-care visits.
Any treatment given to you while you are in the study is part of your normal care and is decided by you and your regular doctor. This study will not change or interfere in any way with the normal care you receive.
The purpose of the study is to collect information on patients 12 years and older, who are starting treatment with dupilumab (also known as DUPIXENT®) for asthma. The sponsor will use the information from the study to better understand real-world patient characteristics, use, effectiveness, and safety of the drug DUPIXENT.
DUPIXENT is approved in multiple countries to treat patients of different ages with asthma,
atopic dermatitis, and/or a long-term blocked up or runny nose (chronic rhinosinusitis) with abnormal growths in the nose (nasal polyps).
For more information contact: Dr Matthew Martin